Spots Global Cancer Trial Database for glasdegib
Every month we try and update this database with for glasdegib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | NCT04051996 | ACUTE MYELOID L... | Glasdegib Decitabine | 18 Years - | Yale University | |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) | NCT04093505 | Acute Myeloid L... | Gemtuzumab Ozog... Gemtuzumab Ozog... Glasdegib Placebo Oral Ta... | 60 Years - | University Hospital Heidelberg | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | NCT04051996 | ACUTE MYELOID L... | Glasdegib Decitabine | 18 Years - | Yale University | |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | NCT04842604 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | Glasdegib Azacitidine | 18 Years - | Pfizer | |
| Acute Myeloid Leukemia Real World Treatment Patterns | NCT04230564 | Leukemia, Myelo... | azacitidine venetoclax glasdegib | 18 Years - | Pfizer | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | NCT04231851 | Acute Myelogeno... Acute Myeloid L... | Glasdegib CPX-351 | 18 Years - | University of California, Irvine | |
| Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) | NCT04093505 | Acute Myeloid L... | Gemtuzumab Ozog... Gemtuzumab Ozog... Glasdegib Placebo Oral Ta... | 60 Years - | University Hospital Heidelberg | |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | NCT04842604 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | Glasdegib Azacitidine | 18 Years - | Pfizer | |
| Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | NCT03226418 | Adult Acute Mye... Secondary Acute... Therapy-Related... | Cytarabine Decitabine Idarubicin Laboratory Biom... Liposome-encaps... Quality-of-Life... Questionnaire A... Azacitidine Venetoclax glasdegib | 60 Years - | University of Nebraska | |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | NCT04842604 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | Glasdegib Azacitidine | 18 Years - | Pfizer | |
| Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML | NCT04168502 | Acute Myeloid L... | Glasdegib Gemtuzumab Ozog... | 18 Years - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | NCT03416179 | Leukemia, Myelo... | glasdegib daunorubicin + ... azacitidine Placebo Placebo glasdegib cytarabine HSCT | 18 Years - | Pfizer | |
| Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | NCT04842604 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | Glasdegib Azacitidine | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
